Erasca, Inc. Common Stock (ERAS) is a publicly traded Healthcare sector company. As of May 21, 2026, ERAS trades at $11.12 with a market cap of $3.19B and a P/E ratio of -25.11. ERAS moved +7.95% today. Year to date, ERAS is +218.63%; over the trailing twelve months it is +768.75%. Its 52-week range spans $1.01 to $24.28. Analyst consensus is buy with an average price target of $20.27. Rallies surfaces ERAS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Erasca Bolsters Cash to $408.5M, Highlights ERAS-0015 NSCLC and PDAC Responses: Erasca ended Q1 with $408.5 million in cash and marketable securities, up from $341.8 million, funding operations into H2 2028 after a $258.8 million public offering. The firm reported strong ERAS-0015 dose escalation responses in KRAS G12X NSCLC and PDAC with low-grade adverse events.
| Metric | Value |
|---|---|
| Price | $11.12 |
| Market Cap | $3.19B |
| P/E Ratio | -25.11 |
| EPS | $-0.44 |
| Dividend Yield | 0.00% |
| 52-Week High | $24.28 |
| 52-Week Low | $1.01 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-124.55M |
| Gross Margin | 0.00% |
11 analysts cover ERAS: 0 strong buy, 9 buy, 1 hold, 1 sell, 0 strong sell. Consensus rating is buy. Average price target: $20.27.